{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:44:14Z","timestamp":1793515454260,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105465","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:06:37Z","timestamp":1783983997000},"page":"105465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immune-related adverse events from checkpoint inhibitors: An evidence-based management review"],"prefix":"10.1016","volume":"225","author":[{"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dottorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Rossitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Parati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Borgonovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Dognini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Petr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Viglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Nicol\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tarantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Callea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2026.105465_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40265-025-02243-4","article-title":"Long-term toxicities of immune checkpoint inhibitors","volume":"85","author":"Abraham","year":"2025","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105465_bib2","article-title":"Fulminant immune checkpoint inhibitor-induced myocarditis and complete heart block in advanced melanoma: a case report","volume":"17","author":"Alhayek","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105465_bib3","first-page":"108","article-title":"How should immune checkpoint inhibitor myocarditis be treated?","volume":"11","author":"Badaan","year":"2025","journal-title":"Cardiooncology"},{"key":"10.1016\/j.critrevonc.2026.105465_bib4","article-title":"Anti-PD-1-induced bullous pemphigoid in a renal transplant recipient","volume":"13","author":"Barnawi","year":"2025","journal-title":"SAGE Open. Med. Case Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105465_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105465_bib6","article-title":"Immune checkpoint inhibitor-induced Miller Fisher syndrome: a case of relapsing symptoms requiring a slow corticosteroid taper","volume":"17","author":"Chapman","year":"2025","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105465_bib7","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.3390\/curroncol31100473","article-title":"Managing select immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"31","author":"Cheema","year":"2024","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105465_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s13256-025-05302-2","article-title":"Treatment-refractory immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in the setting of adjuvant pembrolizumab for resected stage IIC melanoma: a case report","volume":"19","author":"Chow","year":"2025","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.critrevonc.2026.105465_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1712632","article-title":"Safety and effectiveness of immune checkpoint inhibitors in patients with preexisting autoimmune diseases: a systematic review","volume":"16","author":"Dias","year":"2025","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105465_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105465_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1624369","article-title":"Case report: fatal myocarditis and myasthenia gravis induced by immune checkpoint inhibitors: concurrent dual adverse events in an older adult","volume":"15","author":"Fakhreddine","year":"2025","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105465_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2026-116847","article-title":"Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol","volume":"16","author":"Fisher","year":"2026","journal-title":"BMJ Open."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105465_bib13","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105465_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013214","article-title":"JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study","volume":"13","author":"Habib","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105465_bib15","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001847","article-title":"Refractory immune checkpoint inhibitor colitis treated with biologics, Janus kinase inhibition, plasma exchange, and fecal microbiota transplantation","volume":"12","author":"Hearn","year":"2025","journal-title":"ACG Case Rep. J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105465_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013776","article-title":"Steroid-sparing strategies for managing immune-related adverse events","volume":"14","author":"Huang","year":"2026","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105465_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105465_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.critrevonc.2026.105465_bib19","article-title":"Advances in the mechanisms, imaging characteristics and management strategies for immune checkpoint inhibitor-related pneumonitis","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105465_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/carm\/4810248","article-title":"Encephalitis and immune-related complications in a patient treated with nivolumab: a case report","volume":"2025","author":"Lyras","year":"2025","journal-title":"Case Rep. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105465_bib21","article-title":"Drug-induced bullous pemphigoid triggered by immune checkpoint inhibitor Opdualag in an elderly patient with recurrent metastatic melanoma: a case report and treatment course with dupilumab","volume":"17","author":"Moreno","year":"2025","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105465_bib22","article-title":"Pembrolizumab-induced secondary cholangitis: a case report","volume":"17","author":"Muhd Opandi","year":"2025","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105465_bib23","doi-asserted-by":"crossref","DOI":"10.4292\/wjgpt.v16.i4.109485","article-title":"Balancing act: tapering mycophenolate mofetil in immune checkpoint inhibitor hepatitis\u2014strategies, outcomes, and risks","volume":"16","author":"Mujumdar","year":"2025","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105465_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae318","article-title":"Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"30","author":"Naidoo","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105465_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1636452","article-title":"Initial symptoms and diagnostic delay in immune checkpoint inhibitor-related adrenal insufficiency: a systematic review and meta-ethnography of case reports","volume":"16","author":"Ohta","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105465_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.14740\/jocmr6255","article-title":"A challenging case of immune-related organizing pneumonitis following programmed cell death 1 inhibitor therapy in non-small cell lung cancer","volume":"17","author":"Paolozzi","year":"2025","journal-title":"J. Clin. Med. Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105465_bib27","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s00134-025-08155-x","article-title":"Life-threatening immune-related adverse events in the intensive care unit: a narrative review","volume":"51","author":"Pichon","year":"2025","journal-title":"Intensive Care Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105465_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/cancers18010076","article-title":"Age and clinical outcomes of immune checkpoint inhibitor toxicities in Portugal: a decade of pharmacovigilance","volume":"18","author":"Pina-Cabral","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105465_bib29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/jcm15010251","article-title":"Mixed infectious-immune pneumonitis associated with PD-L1 blockade: a case of durvalumab-induced lung injury complicated by human metapneumovirus infection","volume":"15","author":"Pipit\u00f2","year":"2025","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105465_bib30","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/curroncol32120663","article-title":"Steroid-refractory cholestatic immune-mediated hepatitis following nivolumab therapy in an elderly patient with metastatic melanoma: a rare and challenging presentation","volume":"32","author":"Posado-Dominguez","year":"2025","journal-title":"Curr. Oncol."},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105465_bib31","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105465_bib32","doi-asserted-by":"crossref","first-page":"11619","DOI":"10.3390\/ijms262311619","article-title":"Beyond tumor immunity: the disruption of endocrine and infectious homeostasis by immune checkpoint inhibitors","volume":"26","author":"Sch\u00f6nberger","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105465_bib33","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.3390\/cancers17243935","article-title":"Specialist neurology involvement and impact in immune checkpoint inhibitor-related neurotoxicity: experience in a unified healthcare system","volume":"17","author":"Schroeder","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105465_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70069","article-title":"Cytokine release syndrome in solid tumors","volume":"131","author":"Synnott","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105465_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1727312","article-title":"Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients","volume":"16","author":"Thielmann","year":"2025","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105465_bib36","doi-asserted-by":"crossref","first-page":"11646","DOI":"10.3390\/ijms262311646","article-title":"Fatal myocarditis following adjuvant immunotherapy: a case report and literature review","volume":"26","author":"Torounidou","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105465_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1677544","article-title":"Case report: multiple immune related adverse events in a patient with metastatic melanoma","volume":"16","author":"Varada","year":"2025","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105465_bib38","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/jnnp-2025-335998","article-title":"Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist","volume":"96","author":"Willis","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.critrevonc.2026.105465_bib39","article-title":"Immunotherapy rechallenge after ICI-related pneumonitis in lung cancer patients: a retrospective cohort study","volume":"15","author":"Wu","year":"2025","journal-title":"Front. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:58:18Z","timestamp":1787108298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S1040842826003525"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105465","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-related adverse events from checkpoint inhibitors: An evidence-based management review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105465"}}